HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldstein, J. L. Articles by Gierasch, L. M. Search for Related Content PubMed PubMed Citation Articles by Goldstein, J. L. Articles by Gierasch, L. M. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 266, Issue 24, 15575-15578, Aug, 1991

Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase

JL Goldstein, MS Brown, SJ Stradley, Y Reiss and LM Gierasch
Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas 75235.

The protein farnesyltransferase from rat brain was previously shown to be inhibited competitively by tetrapeptides that conform to the consensus Cys-A1-A2-X, where A1 and A2 are aliphatic amino acids and X is methionine, serine, or phenylalanine. In the current studies we use a thin layer chromatography assay to show that most of these tetrapeptides are themselves farnesylated by the purified enzyme. Two classes of tetrapeptides are not farnesylated and therefore act as true inhibitors: 1) those that contain an aromatic residue at the A2 position and 2) those that contain penicillamine (beta,beta- dimethylcysteine) in place of cysteine. The most potent of these pure inhibitors was Cys-Val-Phe-Met, which inhibited farnesyltransferase activity by 50% at less than 0.1 microM. These data indicate that the inclusion of bulky aromatic or methyl residues in a tetrapeptide can abolish prenyl group transfer without blocking binding to the enzyme. This information should be useful in the design of peptides or peptidomimetics that inhibit farnesylation and thus block the action of p21ras proteins in animal cells.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. L. Kilpatrick and J. D. Hildebrandt Sequence Dependence and Differential Expression of G{gamma}5 Subunit Isoforms of the Heterotrimeric G Proteins Variably Processed after Prenylation in Mammalian Cells J. Biol. Chem., May 11, 2007; 282(19): 14038 - 14047. [Abstract] [Full Text] [PDF]

				K. T. Lane and L. S. Beese Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I J. Lipid Res., April 1, 2006; 47(4): 681 - 699. [Abstract] [Full Text] [PDF]

				A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]

				A. T. Reinicke, J. L. Hutchinson, A. I. Magee, P. Mastroeni, J. Trowsdale, and A. P. Kelly A Salmonella typhimurium Effector Protein SifA Is Modified by Host Cell Prenylation and S-Acylation Machinery J. Biol. Chem., April 15, 2005; 280(15): 14620 - 14627. [Abstract] [Full Text] [PDF]

				F. Shao, P. O. Vacratsis, Z. Bao, K. E. Bowers, C. A. Fierke, and J. E. Dixon Biochemical characterization of the Yersinia YopT protease: Cleavage site and recognition elements in Rho GTPases PNAS, February 4, 2003; 100(3): 904 - 909. [Abstract] [Full Text] [PDF]

				S. B. Long, P. J. Hancock, A. M. Kral, H. W. Hellinga, and L. S. Beese The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics PNAS, October 25, 2001; (2001) 241407898. [Abstract] [Full Text] [PDF]

				A. A. Adjei Blocking Oncogenic Ras Signaling for Cancer Therapy J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development J. Clin. Oncol., November 1, 1999; 17(11): 3631 - 3652. [Abstract] [Full Text] [PDF]

				N. E. KOHL Farnesyltransferase Inhibitors: Preclinical Development Ann. N.Y. Acad. Sci., January 1, 1999; 886(1): 91 - 102. [Abstract] [Full Text] [PDF]

				J. H. Overmeyer, A. L. Wilson, R. A. Erdman, and W. A. Maltese The Putative "Switch 2" Domain of the Ras-related GTPase, Rab1B, Plays an Essential Role in the Interaction with Rab Escort Protein Mol. Biol. Cell, January 1, 1998; 9(1): 223 - 235. [Abstract] [Full Text]

				A. Vogt, Y. Qian, M. A. Blaskovich, R. D. Fossum, A. D. Hamilton, and S. M. Sebti A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing J. Biol. Chem., January 13, 1995; 270(2): 660 - 664. [Abstract] [Full Text] [PDF]

				N. Kohl, S. Mosser, S. deSolms, E. Giuliani, D. Pompliano, S. Graham, R. Smith, E. Scolnick, A Oliff, and J. Gibbs Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor Science, June 25, 1993; 260(5116): 1934 - 1937. [Abstract] [PDF]

				G. James, J. Goldstein, M. Brown, T. Rawson, T. Somers, R. McDowell, C. Crowley, B. Lucas, A. Levinson, and J. Marsters Jr Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells Science, June 25, 1993; 260(5116): 1937 - 1942. [Abstract] [PDF]

				C. Figueroa, J. Taylor, and A. B. Vojtek Prenylated Rab Acceptor Protein Is a Receptor for Prenylated Small GTPases J. Biol. Chem., July 20, 2001; 276(30): 28219 - 28225. [Abstract] [Full Text] [PDF]

				S. B. Long, P. J. Hancock, A. M. Kral, H. W. Hellinga, and L. S. Beese The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics PNAS, November 6, 2001; 98(23): 12948 - 12953. [Abstract] [Full Text] [PDF]